{
    "organizations": [],
    "uuid": "fd6b5929bd2d69b182bc9ad70fa4eec3d91c699c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-zafgen-reports-q4-loss-per-share-0/brief-zafgen-reports-q4-loss-per-share-0-48-idUSASB0C91V",
    "ord_in_thread": 0,
    "title": "BRIEF-Zafgen Reports Q4 Loss Per Share $0.48",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 6 (Reuters) - Zafgen Inc:\n* ZAFGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS; ANNOUNCES POSITIVE INTERIM DATA FROM ONGOING ZGN-1061 PHASE 2 PROOF-OF-CONCEPT TRIAL IN PATIENTS WITH TYPE 2 DIABETES\n* Q4 LOSS PER SHARE $0.48 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-07T05:23:00.000+02:00",
    "crawled": "2018-03-07T19:22:50.055+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "zafgen",
        "inc",
        "zafgen",
        "report",
        "fourth",
        "quarter",
        "full",
        "year",
        "financial",
        "result",
        "announces",
        "positive",
        "interim",
        "data",
        "ongoing",
        "phase",
        "trial",
        "patient",
        "type",
        "diabetes",
        "q4",
        "loss",
        "per",
        "share",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}